Antonio Camera
A5089414738- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer Research and Treatments
- Virus-based gene therapy research
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Nanoplatforms for cancer theranostics
- Immune cells in cancer
- Cancer Diagnosis and Treatment
- Diabetic Foot Ulcer Assessment and Management
- Integrated Circuits and Semiconductor Failure Analysis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Hemophilia Treatment and Research
- Metastasis and carcinoma case studies
- Autoimmune and Inflammatory Disorders Research
- Sarcoma Diagnosis and Treatment
- Mesenchymal stem cell research
- Oral and Craniofacial Lesions
- Lipid metabolism and disorders
- Congenital Diaphragmatic Hernia Studies
Immunocore (United Kingdom)
2023-2025
Bambino Gesù Children's Hospital
2018-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2024
University of Palermo
2007-2008
Ospedale Antonio Cardarelli
2000
Istituto Dermopatico dell'Immacolata
1994-1996
Uveal melanoma (UM) is the most common intraocular cancer in adults, with metastatic disease (mUM) occurring approximately half of patients. Tebentafusp, an immune-mobilizing monoclonal T cell receptor against (ImmTAC), a therapeutic shown to improve overall survival (OS) HLA-A*02:01+ adult patients mUM. Here we investigate impact tumor-associated macrophages (TAM) on ImmTAC activity. In vitro, M2 inhibit ImmTAC-mediated tumor-killing dose-dependent and contact-dependent manner. Accordingly,...
Abstract Purpose: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, endocrine side effects. We investigated whether chimeric antigen receptor (CAR) T cells directed toward disialoganglioside GD2 can represent potentially more effective treatment with reduced long-term Experimental Design: expression...
Abstract Medulloblastoma is the most frequent malignant childhood brain tumor with a high morbidity. Identification of new therapeutic targets would be instrumental in improving patient outcomes. We evaluated expression tumor-associated antigen PRAME biopsies from 60 patients medulloblastoma. was detectable 82% tissues independent molecular and histopathologic subgroups. High also correlated worse overall survival. next investigated relevance as target for immunotherapy. cells were targeted...
The prognosis of many patients with chemotherapy-refractory or multiply relapsed CD30+ non-Hodgkin Lymphoma (NHL) Hodgkin lymphoma (HL) still remains poor, and novel therapeutic approaches are warranted to address this unmet clinical need. In light consideration, we designed pre-clinically validated a Chimeric Antigen Receptor (CAR) construct characterized by anti-CD30 single-chain variable-fragment cassette, linked CD3ζ the signaling domains two costimulatory molecules, namely either...
T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in patients relapsed/refractory B-cell precursor acute lymphoblastic leukemia or non-Hodgkin lymphoma. Despite the reported exciting clinical results, CAR-T cell approach needs efforts to improve safety profile, limiting occurrence of adverse events given this treatment. Besides most common side effects, such as cytokine release syndrome and cell–related encephalopathy syndrome, another potential issue...
Medulloblastoma (MB) is a childhood malignant brain tumour comprising four main subgroups characterized by different genetic alterations and rate of mortality. Among MB subgroups, patients with enhanced levels the c-MYC oncogene (MBGroup3) have poorest prognosis. Here we identify previously unrecognized role pro-autophagy factor AMBRA1 in regulating MB. We demonstrate that expression depends on correlates Group 3 patient poor prognosis; also, knockdown reduces stem potential, growth...
Immune escape mechanisms employed by neuroblastoma (NB) cells include secretion of immunosuppressive factors disrupting effective antitumor immunity. The use cellular therapy to treat solid tumors needs be implemented. Killing activity anti-GD2 Chimeric Antigen Receptor (CAR) T or natural killer (NK) against target NB was assessed through coculture experiments and quantified FACS analysis. ELISA assay used quantify interferon-γ (IFNγ) secreted NK CAR cells. Real Time PCR Western Blot were...
Tebentafusp is the first T-cell receptor-based bispecific protein approved for clinical use in HLA-A*02:01+ adult patients with unresectable/metastatic uveal melanoma. It redirects T-cells toward gp100-expressing target cells, frequently inducing skin-related early adverse events. This study investigated immunological and cellular responses using single-cell spatial analysis of skin biopsies from metastatic melanoma treated tebentafusp. 81.8% developed acute cutaneous events, which...
Chimeric antigen receptor T-cells (CAR T-cells) for the treatment of relapsing/refractory B-cell precursor acute lymphoblastic leukemia have led to exciting clinical results. However, CAR T-cell approaches revealed a potential risk CD19-/CAR+ leukemic relapse due inadvertent transduction cells. Background Methods We evaluated impact high percentage blast contamination in patient-derived starting material (SM) on drug product (DP) manufacturing. In vitro as well vivo models were employed...
<p>Supplemental Figure 12. DAOY-GFP tumor bearing-mice treated with Tazemetostat to evaluate GD2 upregulation in vivo.</p>
<p>Supplemental Figure 5. Real-Time killing assay of CAR.GD2 T-cells vs DAOY-GFP cell line.</p>
<div>AbstractPurpose:<p>Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, endocrine side effects. We investigated whether chimeric antigen receptor (CAR) T cells directed toward disialoganglioside GD2 can represent potentially more effective treatment with reduced long-term...
<p>Supplemental Figure 6. CAR.GD2 T-cells spare the elimination of MB cells with a dim expression GD2.</p>
<p>Supplemental Figure 14. Orthotopic PDX mouse model of human MED-411 FH mCherry/Luc cell line to evaluate anti-tumor activity CAR.GD2 T-cells.</p>
<p>Supplemental Video 2. IncuCyte® live-cell System video of Cytotoxic activity NT or CAR.GD2 T-cells vs DAOY-GFP-FF-Luc cell line. The shows 84 hours tumor growth (DAOY line) with only (A) and cells co-cultured (B) (C).</p>
<p>Supplemental Figure 8. Tazemetostat did not modulate GD2 expression in normal cells.</p>
<p>Supplemental Figure 17. Evaluation of the NT T-cell infiltration in MB xenograft mouse model.</p>